Abstracts tagged "Sjogren’s syndrome"

Abstract Number: 2933 • 2014 ACR/ARHP Annual Meeting
Metabolic Syndrome, Adipocytokines and Inflammation in Sjögren’s Syndrome
Kristopherson Lustosa Augusto¹, Eloisa Bonfá², Rosa M. R. Pereira¹, Cleonice Bueno³, Vilma S. T. Viana⁴ and Sandra G. Pasoto⁵, ¹Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ²Rheumatology Division, University of Sao Paulo, Sao Paulo, Brazil, ³Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ⁴Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁵Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil
Background/Purpose Systemic inflammation has been linked to increased frequency of metabolic syndrome (MetS) in autoimmune diseases. However, there are no studies concerning the frequency of…
Abstract Number: 2540 • 2014 ACR/ARHP Annual Meeting
Sjö™, an Advanced Diagnostic Panel for Detection of Sjögren’s Syndrome Autoantibodies
Mark Jasek¹, Kishore Malyavantham², Lakshmanan Suresh³, Julian Ambrus⁴ and Dennis Pardo⁵, ¹Medical and Scientific Affairs, Nicox Inc, Fort Worth, TX, ²Office of Science & Technology, IMMCO Diagnostics Inc., Amherst, NY, ³60 Pineview Drive, State University of New York/Buffalo, Buffalo, NY, ⁴Division of Allergy, Immunology and Rheumatology, Department of Medicine, State University of New York at Buffalo, Buffalo, NY, ⁵Professional Affairs, Nicox Inc, Fort Worth, TX
Background/Purpose Sjögren’s syndrome (SS) is a complex autoimmune disease involving the salivary and lacrimal glands along with various systemic manifestations. It is a difficult disease to…
Abstract Number: 524 • 2014 ACR/ARHP Annual Meeting
Distinct Patterns of DNA Methylation in Labial Salivary Gland Tissue Based on Sjögren’s Syndrome Disease Status
Michael Cole¹, Xiaorong Shao¹, Diana Quach², Hong L. Quach², Lisa F. Barcellos² and Lindsey A. Criswell³, ¹Genetic Epidemiology and Genomics Lab, Division of Epidemiology, University of California, Berkeley, Berkeley, CA, ²Epidemiology, University of California, Berkeley, Berkeley, CA, ³Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA
Background/Purpose Sjögren’s Syndrome (SS, OMIM #270150) is a chronic, multi-system autoimmune disease characterized by progressive destruction of the exocrine glands, with subsequent mucosal and conjunctival…
Abstract Number: 2934 • 2014 ACR/ARHP Annual Meeting
Abatacept reduces Circulating Effector Memory T-Helper Cells in Patients with Primary Sjögren’s Syndrome
Gwenny Verstappen¹, Wayel H. Abdulahad², Petra M. Meiners³, Suzanne Arends⁴, Silvia Beijer-Liefers⁵, Arjan Vissink³, Frans G.M. Kroese⁴ and Hendrika Bootsma⁴, ¹Rheumatology & Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ³Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁴Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁵University Medical Center Groningen, University of Groningen, Groningen, Netherlands
Background/Purpose In an open-label proof of concept study, Abatacept has been identified as an effective and safe treatment modality in primary Sjögren’s syndrome (pSS). Abatacept…
Abstract Number: 2533 • 2014 ACR/ARHP Annual Meeting
Utility of the American-European Consensus Group and American College of Rheumatology Classification Criteria for Sjögren’s Syndrome in Patients with Systemic Autoimmune Diseases in the Clinical Setting
Gabriela Hernandez-Molina¹, Carmen Ávila-Casado², Carlos Núñez-Álvarez³, Carlos Hernández-Hernández⁴, Maria Luisa Calderillo⁴, Martha Marroquín⁴, Claudia Recillas-Gispert⁵, Juanita Romero-Díaz³ and Jorge Sánchez-Guerrero⁶, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ²Pathology, University Health Network, Toronto Canada., Toronto, ON, Canada, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ⁴Dental Service, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ⁵Ophtalmology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ⁶Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada
Background/Purpose: To evaluate the feasibility and performance of the AECG and ACR Classification Criteria for Sjögren’s syndrome (SS) in patients with systemic autoimmune diseases. Methods:…
Abstract Number: 523 • 2014 ACR/ARHP Annual Meeting
Serum CXCL4 Is Increased in Patients with Primary Sjögren’s Syndrome and Is Associated with Features of Microvascular Impairment
Rosaria Irace¹, Antonella Riccardi¹, Daniela Iacono¹, Luciana Pellecchia¹, Lucia Vicedomini¹, Gabriele Valentini² and Serena Vettori¹, ¹Internal and Experimental Medicine, Second University of Naples, Naples, Italy, ²Internal and Experimental Medicine, Second University of Naples, Napoli, Italy
Background/Purpose CXCL4 is a pleiotropic antiangiogenic and immunomodulatory chemokine. We aimed to investigate CXCL4 serum levels in primary Sjögren’s syndrome (pSS) and looked for associations…
Abstract Number: 2806 • 2014 ACR/ARHP Annual Meeting
Characteristic Phenotype of Peripheral Blood Lymphocytes in Patients with IgG4-Related Disease, Comparing to Primary Sjögren Syndrome and Healthy Controls
Shintaro Hirata, Shingo Nakayamada, Satoshi Kubo, Maiko Yoshikawa, Naoki Yunoue, Kazuhisa Nakano, Kunihiro Yamaoka, Kazuyoshi Saito and Yoshiya Tanaka, The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose : IgG4-related disease (IgG4-RD) is a systemic disease that is characterized by the infiltration of IgG4-positive plasma cells and T cells into various organs.…
Abstract Number: 2531 • 2014 ACR/ARHP Annual Meeting
Risk of Venous Thromboembolism in Patients with Sjogren’s Syndrome: A Systematic Review and Meta-Analysis
Patompong Ungprasert¹, Charat Thongprayoon², Karn Wijarnpreecha³, Wisit Cheungpasitporn², Praveen Ratanasrimetha⁴ and Promporn Suksaranjit⁵, ¹Department of Internal medicine, Bassett medical center, Cooperstown, NY, ²Department of Medicine, Mayo clinic, Rochester, MN, ³Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, ⁴Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, ⁵Department of Cardiology, University of Utah School of Medicine, Salt Lake City, UT
Risk of Venous Thromboembolism in Patients with Sjogren's Syndrome: A Systematic Review and Meta-analysisBackground/Purpose: Venous thromboembolism (VTE) is a common medical problem with a significant…
Abstract Number: 521 • 2014 ACR/ARHP Annual Meeting
CXCL13 Serum Levels Is Associated with Lymphoma, High B Cells Markers and Diseases activity in Primary Sjögren ’s Syndrome Patients
Gaetane Nocturne¹, Olivier Fogel², Philippe Dieude³, Jean Jacques Dubost⁴, Anne-Laure Fauchais⁵, Vincent Goeb⁶, Eric Hachulla⁷, Claire Larroche⁸, Véronique Le Guern⁹, Jacques Morel¹⁰, Aleth Perdriger¹¹, Xavier Puéchal¹², Stephanie Rist Bouillon¹³, Valerie Devauchelle¹⁴, Damien Sène¹⁵, O Vittecoq¹⁶, Corinne Miceli-Richard¹⁷, Jacques Gottenberg¹⁸ and Xavier Mariette¹⁹, ¹INSERM U1012, Paris sud university, Le Kremlin Bicetre, France, ²INSERM U1012, Paris sud university, Le Kremlin Bicêtre, France, ³Rhumatologie, Hopital Bichat Claude Bernard, Paris, France, ⁴Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France, ⁵Department of Internal Medicine A, Dupuytren Hospital, Limoges University Hospital, Limoges, France, ⁶Rhumatology Department, University Hospital, AMIENS, France, ⁷Faculté de Médecine Henri Warembourg, Université Lille Nord de France, Lille, France, ⁸Internal Medicine, Avicenne Hospital,, Assistance Publique des Hôpitaux de Paris,, Bobigny, France, ⁹Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ¹⁰Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, ¹¹Rhumatologie, Rennes, France, ¹²National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ¹³Rhumatologie, Hopital La Source, La Source, France, ¹⁴Rheumatology, Brest university medical school, EA 2216, Lab Ex, INSERM, IGO,UBO and CHU de la Cavale Blanche,, Brest, France, ¹⁵Hopital Lariboisière, service de Médecine Interne, Paris, France, ¹⁶Rouen University Hospital & Inserm U905, Rouen, France, ¹⁷Rheumatology Department, Université Paris-Sud 11, Bicêtre Hospital,, Kremlin Bicêtre, France, ¹⁸Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹⁹rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France
Background/Purpose: Development of non-Hodgkin lymphoma (NHL) is one of the most severe complications associated with pSS. It affects 5-10% of the patients. Definition of predictive…
Abstract Number: 2725 • 2014 ACR/ARHP Annual Meeting
Enhanced Expression of CCL25 to Facilitate Increased Numbers of CCR9-Expressing Tfh-like Cells in Salivary Glands of Primary Sjögren’s Syndrome Patients
S.L.M. Blokland^1,2, M.R. Hillen^1,2, A.a. Kruize², A. Kislat³, S. Meller³, B. Homey³, G.M. Smithson⁴, J. Zalevsky⁵, T.R.D.J. Radstake² and J.a.G. van Roon², ¹Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Department of Dermatology, University of Düsseldorf, Medical Faculty, Düsseldorf, Germany, ⁴Takeda Pharmaceuticals International, Chicago, IL, ⁵Takeda California, San Diego, CA
Background/Purpose In primary Sjögren’s syndrome (pSS) B cell activation and autoantibody secretion are hallmark immunopathological features. Specific lymphoid organization (including germinal centers) is associated with…
Abstract Number: 2174 • 2014 ACR/ARHP Annual Meeting
MicroRNA-146a in Salivary Gland Epithelial Cells Inhibits Co-Stimulatory Molecule CD80 Expression and Increases Autoreactive T Cell Activation in Sjögren’s Syndrome
Adrienne Gauna¹, Jun-O Jin^2,3, Qing Yu², Carol Stewart¹ and Seunghee Cha¹, ¹Oral and Maxillofacial Diagnostic Sciences, University of Florida, Gainesville, FL, ²Department of Immunology and Infectious Diseases, The Forsyth Institute, Cambridge, MA, ³Shanghai Public Health Clinical Center, Fudan University Shanghai Medical College, Shanghai, China
Background/Purpose: Sjögren’s syndrome (SS) causes severe dry mouth and eyes. The presence of immune cell infiltration in the salivary (SG) and lacrimal glands suggests a…
Abstract Number: 520 • 2014 ACR/ARHP Annual Meeting
Genetic Variant and High Levels of CCL11 in Serum Are Associated with the Occurrence of Lymphoma and Disease Activity in Primary Sjögren’s Syndrome Patients (pSS)
Gaetane Nocturne¹, Olivier Fogel², Joanne Nititham³, Kimberly E. Taylor⁴, Philippe Dieude⁵, Jean Jacques Dubost⁶, Anne-Laure Fauchais⁷, Vincent Goëb⁸, Eric Hachulla⁹, Claire Larroche¹⁰, Véronique Le Guern¹¹, Jacques Morel¹², Aleth Perdriger¹³, Xavier Puéchal¹⁴, Stephanie Rist Bouillon¹⁵, Alain Saraux¹⁶, Damien Sène¹⁷, Olivier Vittecoq¹⁸, Lindsey A. Criswell¹⁹, Corinne Miceli-Richard²⁰, Jacques Gottenberg²¹ and Xavier Mariette²², ¹INSERM U1012, Paris sud university, Le Kremlin Bicetre, France, ²INSERM U1012, Paris sud university, Le Kremlin Bicêtre, France, ³University of California San Francisco, 374 Parnassus Avenue, San Francisco, CA, ⁴Department of Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ⁵Rhumatologie, Hopital Bichat Claude Bernard, Paris, France, ⁶Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France, ⁷Department of Internal Medicine A, Dupuytren Hospital, Limoges University Hospital, Limoges, France, ⁸Rheumatology, Amiens University Hospital, Amiens, France, ⁹Faculté de Médecine Henri Warembourg, Université Lille Nord de France, Lille, France, ¹⁰Internal Medicine, Avicenne Hospital,, Assistance Publique des Hôpitaux de Paris,, Bobigny, France, ¹¹Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ¹²Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, ¹³Rhumatologie, Rennes, France, ¹⁴National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ¹⁵Rhumatologie, Hopital La Source, La Source, France, ¹⁶CHU Brest and EA 2216, UBO, Brest, France, ¹⁷Hopital Lariboisière, service de Médecine Interne, Paris, France, ¹⁸Rheumatology, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ¹⁹Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ²⁰Rheumatology Department, Université Paris-Sud 11, Bicêtre Hospital,, Kremlin Bicêtre, France, ²¹Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²²rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France
Background/Purpose: Development of non-Hodgkin lymphoma (NHL) is one of the most severe complications of pSS. It occurs in 5-10% of the patients. A more accurate…
Abstract Number: 2539 • 2014 ACR/ARHP Annual Meeting
Antibodies to Human Interferon-Inducible Protein-16 Are Present in Primary Sjögren’s Syndrome and Systemic Lupus, but Are Rare in Dermatomyositis
Alan N. Baer¹, Michelle Petri², David Fiorentino³, Tao Wang⁴, Jungsan Sohn⁴, Antony Rosen¹ and Livia Casciola-Rosen⁵, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, ⁴Biophysics and Biophysical Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Center Tower Ste 5300, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Interferon inducible protein-16 (IFI16) is an intracellular DNA receptor involved in innate immunity. We evaluated the frequency and clinical significance of anti-IFI16 antibodies in…
Abstract Number: 1799 • 2014 ACR/ARHP Annual Meeting
Elevated Indoleamine-2,3-Dioxygenase (IDO) Activity and Kynurinene-3-Monooxygenase (KMO) Expression in Interferon Positive Primary Sjogrens Syndrome Patients Is Associated with Increased CD25^hiFoxP3⁺regulatory Tcells: A Skew Towards Neurotoxicity or an Attempt to Rescue?
Naomi I Maria¹, Cornelia G. van Helden-Meeuwsen¹, Zana Brkic¹, Sandra M.J. Paulissen^1,2, Virgil A. Dalm¹, Paul L. van Daele¹, P. Martin van Hagen¹, Sinead M. Gibney^1,3, Andrew Harkin³, Hemmo A. Drexhage¹, Erik Lubberts^1,2 and Marjan A. Versnel¹, ¹Erasmus Medical Center, Immunology, Rotterdam, Netherlands, ²Erasmus Medical Center, Rheumatology, Rotterdam, Netherlands, ³Trinity College Institute of Neuroscience, Neuropsychopharmacology, Dublin, Ireland
Background/Purpose: A role for indoleamine-2,3-dioxygenase (IDO) in suppression of effector T-cell function and promotion of regulatory T-cell (Treg) differentiation has been described. IDO - the…
Abstract Number: 150 • 2014 ACR/ARHP Annual Meeting
Ultrasonographic Evaluation of Major Salivary Glands in Primary Sjogren’s Syndrome: Comparison of Two Scoring Systems and Diagnostic Value of Sonoelastography
Xia Zhang¹, Jing He² and Zhanguo Li³, ¹Department of Rheumatology & immunology, Peking University People's Hospital, Beijing, China, ²Department of Rheumatology & Immunology, Peking University People's Hospital, Beijing, China, ³Rheum/Immunology, Peking University People's Hospital, Beijing, China
Background/Purpose Primary Sjogren’s syndrome (pSS) is a chronic systemic autoimmune disease characterized by clinically xerophthalmia and xerostomia. Those standard tests of salivary glands involvement has…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.